University of California, San Francisco: Malaria trials

The registry lists 31 Malaria studies with University of California, San Francisco as lead sponsor. 3 are open to participants now and 8 have results posted.

Phase 1 2Phase 2 4Phase 3 11Phase 4 6No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Integrating the Guardian Spatial Emanator Within AVENIR IINot yet recruitingNCT07712263Not applicable
• Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community TransmissionNot yet recruitingNCT07246525Phase 4
• FocaL Mass Drug Administration for Vivax Malaria EliminationRecruitingNCT05690841Phase 3
• LLIN Evaluation in Uganda ProjectCompletedNCT04566510Not applicableResults posted
• Gut and Azithromycin Mechanisms in Infants and Children IICompletedNCT04315272Phase 4Results posted
• Extended Duration Artemether-lumefantrine Treatment for Malaria in ChildrenCompletedNCT03453840Phase 4Results posted
• Prevention of Malaria in HIV-uninfected Pregnant Women and InfantsCompletedNCT02793622Phase 3Results posted
• Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2)CompletedNCT02282293Phase 3Results posted
• Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant WomenCompletedNCT00993031Phase 3Results posted
• HIV Protease Inhibitors for the Prevention of Malaria in Ugandan ChildrenCompletedNCT00978068Phase 3Results posted
• Chemopreventive Therapy for Malaria in Ugandan ChildrenCompletedNCT00948896Phase 3Results posted
• Leveraging the Seasonal Malaria Chemoprevention Platform to Address Malaria and MalnutritionActive, not recruitingNCT06599593Not applicable
• LLIN Evaluation in Uganda Project (LLINEUP3)CompletedNCT05950191Not applicable
• CHILD (Child Health and Infection With Low Density) MalariaCompletedNCT05567016Not applicable
• Primaquine Double Dose for Radical Cure of Plasmodium Vivax in ColombiaWithdrawnNCT05232227Phase 2/3
• Association Between Drug Levels, Malaria, and Antimalarial Resistance in the Setting of Seasonal Malaria ChemopreventionCompletedNCT04969185
• Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination ActivitiesCompletedNCT04864444Not applicable
• Malaria High-Risk Populations in NamibiaCompletedNCT04094727Phase 4
• Phase 2 Efficacy Study of Primaquine and Methylene BlueCompletedNCT02831023Phase 2
• Evaluation of Reactive Focal Mass Drug Administration (rfMDA) +/- Reactive Focal Vector Control (RAVC) in NamibiaCompletedNCT02610400Phase 3
• Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in MaliCompletedNCT02535767Phase 1/2
• Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in SwazilandCompletedNCT02315690Phase 3
• Phase2a Primaquine Dose Escalation StudyCompletedNCT01743820Phase 2
• Antimalarial Pharmacology in Children and Pregnant Women in UgandaCompletedNCT01717885
• Sulphadoxine-Pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in UgandaWithdrawnNCT01184911Phase 4
• Pharmacokinetics of Dihydroartemisinin-Piperaquine in the Treatment of Uncomplicated Malaria in Children in Burkina FasoCompletedNCT00845533Phase 4
• Training in Fever Case Management With Rapid Diagnostic Tests (RDTs) for Malaria in UgandaCompletedNCT00716599Not applicable
• Interactions Between HIV and Malaria in African ChildrenCompletedNCT00527800Phase 3
• Rapid Diagnostic Tests (RDTs) for Malaria in Kampala, UgandaCompletedNCT00327964
• Drug Interaction Study Between Antimalarial and Anti-HIV MedicationsCompletedNCT00266058Phase 1
• Longitudinal Antimalarial Combinations in UgandaCompletedNCT00123552Phase 3